Vagner Deuel de O. Tavares , Geovan Menezes de Sousa , Felipe B. Schuch , Joseph Firth , Lin Yang , Maria Stein , Bruno Marson Malagodi , Raissa Nóbrega , Renali Camilo Bezerra , Alexandre Guimarães Gouveia , Jaime Eduardo Hallak , Emerson Arcoverde , Colleen Cuthbert , Nicole Leite Galvão-Coelho
{"title":"平衡皮质醇:在一项针对重度抑郁症的随机对照试验中,情感调节和多模式运动作为药物治疗的辅助作用","authors":"Vagner Deuel de O. Tavares , Geovan Menezes de Sousa , Felipe B. Schuch , Joseph Firth , Lin Yang , Maria Stein , Bruno Marson Malagodi , Raissa Nóbrega , Renali Camilo Bezerra , Alexandre Guimarães Gouveia , Jaime Eduardo Hallak , Emerson Arcoverde , Colleen Cuthbert , Nicole Leite Galvão-Coelho","doi":"10.1016/j.mhpa.2025.100687","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The adjunctive effects of exercise on cortisol levels in people with major depressive disorders (MDD) are equivocal. Therefore, we aimed to compare pharmacotherapy alone (antidepressants) versus an adjunct intervention of pharmacotherapy plus exercise on cortisol levels over 12 weeks.</div></div><div><h3>Methods</h3><div>Serum cortisol were assessed before (baseline–t0), during (Week 5–t1), and at the end of treatment (Week 12–t2). The exercise intervention focused on promoting perceived effort, enjoyment, and overall pleasure throughout the multimodal exercise sessions. The study enrolled 59 adults and randomly allocated them into two groups: exercise group (EG; n= 26,76.9% females, mean age 28.5 years; normal cortisol- EG-CN, n= 18 and hypercortisolemia- EG-HC, n = 7) and control group (CG, n= 29,72.40% females, mean age 26.0 years/normal cortisol CO-CN, n= 17 and hypercortisolemia- CO-HC, n= 11).</div></div><div><h3>Results</h3><div>No changes in cortisol levels were observed over time in both groups (EG and CO). However, in subgroup analysis, participants with hypercortisolemia reduced their cortisol levels regardless of the intervention allocation. At the end of the study, hypercortisolemic MDD participants of EG showed similar cortisol levels with those of the normal cortisol group (EG-CN) [p= .507,d= −.22(-1.11,.67)], while hypercortisolemic MDD participants under exclusive pharmacotherapy (control group) continued to show significantly higher levels than CO-CN [p=<.0001,d= −2.32(-3.41,-1.20)].</div></div><div><h3>Conclusion</h3><div>Our preliminary findings suggest that, in people with MDD and hypercortisolemia, a structured, multimodal, affect-adjusted, and supervised exercise program along with pharmacotherapy normalized cortisol levels. Notwithstanding, neither pharmacotherapy nor exercise plus pharmacotherapy changed cortisol levels among those with normal cortisol levels at baseline. These results indicate that combining exercise with pharmacotherapy may be effective in reducing cortisol levels specifically in individuals with MDD and elevated cortisol. However, further studies with larger samples are needed to explore this response more thoroughly.</div></div>","PeriodicalId":51589,"journal":{"name":"Mental Health and Physical Activity","volume":"29 ","pages":"Article 100687"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Balancing Cortisol: The role of affect-adjusted and multimodal exercise as an adjunct to pharmacotherapy in a randomized controlled trial for major depressive disorder\",\"authors\":\"Vagner Deuel de O. Tavares , Geovan Menezes de Sousa , Felipe B. Schuch , Joseph Firth , Lin Yang , Maria Stein , Bruno Marson Malagodi , Raissa Nóbrega , Renali Camilo Bezerra , Alexandre Guimarães Gouveia , Jaime Eduardo Hallak , Emerson Arcoverde , Colleen Cuthbert , Nicole Leite Galvão-Coelho\",\"doi\":\"10.1016/j.mhpa.2025.100687\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The adjunctive effects of exercise on cortisol levels in people with major depressive disorders (MDD) are equivocal. Therefore, we aimed to compare pharmacotherapy alone (antidepressants) versus an adjunct intervention of pharmacotherapy plus exercise on cortisol levels over 12 weeks.</div></div><div><h3>Methods</h3><div>Serum cortisol were assessed before (baseline–t0), during (Week 5–t1), and at the end of treatment (Week 12–t2). The exercise intervention focused on promoting perceived effort, enjoyment, and overall pleasure throughout the multimodal exercise sessions. The study enrolled 59 adults and randomly allocated them into two groups: exercise group (EG; n= 26,76.9% females, mean age 28.5 years; normal cortisol- EG-CN, n= 18 and hypercortisolemia- EG-HC, n = 7) and control group (CG, n= 29,72.40% females, mean age 26.0 years/normal cortisol CO-CN, n= 17 and hypercortisolemia- CO-HC, n= 11).</div></div><div><h3>Results</h3><div>No changes in cortisol levels were observed over time in both groups (EG and CO). However, in subgroup analysis, participants with hypercortisolemia reduced their cortisol levels regardless of the intervention allocation. At the end of the study, hypercortisolemic MDD participants of EG showed similar cortisol levels with those of the normal cortisol group (EG-CN) [p= .507,d= −.22(-1.11,.67)], while hypercortisolemic MDD participants under exclusive pharmacotherapy (control group) continued to show significantly higher levels than CO-CN [p=<.0001,d= −2.32(-3.41,-1.20)].</div></div><div><h3>Conclusion</h3><div>Our preliminary findings suggest that, in people with MDD and hypercortisolemia, a structured, multimodal, affect-adjusted, and supervised exercise program along with pharmacotherapy normalized cortisol levels. Notwithstanding, neither pharmacotherapy nor exercise plus pharmacotherapy changed cortisol levels among those with normal cortisol levels at baseline. These results indicate that combining exercise with pharmacotherapy may be effective in reducing cortisol levels specifically in individuals with MDD and elevated cortisol. However, further studies with larger samples are needed to explore this response more thoroughly.</div></div>\",\"PeriodicalId\":51589,\"journal\":{\"name\":\"Mental Health and Physical Activity\",\"volume\":\"29 \",\"pages\":\"Article 100687\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Health and Physical Activity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1755296625000183\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health and Physical Activity","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1755296625000183","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Balancing Cortisol: The role of affect-adjusted and multimodal exercise as an adjunct to pharmacotherapy in a randomized controlled trial for major depressive disorder
Background
The adjunctive effects of exercise on cortisol levels in people with major depressive disorders (MDD) are equivocal. Therefore, we aimed to compare pharmacotherapy alone (antidepressants) versus an adjunct intervention of pharmacotherapy plus exercise on cortisol levels over 12 weeks.
Methods
Serum cortisol were assessed before (baseline–t0), during (Week 5–t1), and at the end of treatment (Week 12–t2). The exercise intervention focused on promoting perceived effort, enjoyment, and overall pleasure throughout the multimodal exercise sessions. The study enrolled 59 adults and randomly allocated them into two groups: exercise group (EG; n= 26,76.9% females, mean age 28.5 years; normal cortisol- EG-CN, n= 18 and hypercortisolemia- EG-HC, n = 7) and control group (CG, n= 29,72.40% females, mean age 26.0 years/normal cortisol CO-CN, n= 17 and hypercortisolemia- CO-HC, n= 11).
Results
No changes in cortisol levels were observed over time in both groups (EG and CO). However, in subgroup analysis, participants with hypercortisolemia reduced their cortisol levels regardless of the intervention allocation. At the end of the study, hypercortisolemic MDD participants of EG showed similar cortisol levels with those of the normal cortisol group (EG-CN) [p= .507,d= −.22(-1.11,.67)], while hypercortisolemic MDD participants under exclusive pharmacotherapy (control group) continued to show significantly higher levels than CO-CN [p=<.0001,d= −2.32(-3.41,-1.20)].
Conclusion
Our preliminary findings suggest that, in people with MDD and hypercortisolemia, a structured, multimodal, affect-adjusted, and supervised exercise program along with pharmacotherapy normalized cortisol levels. Notwithstanding, neither pharmacotherapy nor exercise plus pharmacotherapy changed cortisol levels among those with normal cortisol levels at baseline. These results indicate that combining exercise with pharmacotherapy may be effective in reducing cortisol levels specifically in individuals with MDD and elevated cortisol. However, further studies with larger samples are needed to explore this response more thoroughly.
期刊介绍:
The aims of Mental Health and Physical Activity will be: (1) to foster the inter-disciplinary development and understanding of the mental health and physical activity field; (2) to develop research designs and methods to advance our understanding; (3) to promote the publication of high quality research on the effects of physical activity (interventions and a single session) on a wide range of dimensions of mental health and psychological well-being (eg, depression, anxiety and stress responses, mood, cognitive functioning and neurological disorders, such as dementia, self-esteem and related constructs, psychological aspects of quality of life among people with physical and mental illness, sleep, addictive disorders, eating disorders), from both efficacy and effectiveness trials;